WuXi Biologics (Cayman) Future Growth
Future criteria checks 3/6
WuXi Biologics (Cayman) is forecast to grow earnings and revenue by 18.9% and 10.8% per annum respectively. EPS is expected to grow by 17.7% per annum. Return on equity is forecast to be 9.4% in 3 years.
Key information
18.9%
Earnings growth rate
17.7%
EPS growth rate
Life Sciences earnings growth | 58.0% |
Revenue growth rate | 10.8% |
Future return on equity | 9.4% |
Analyst coverage | Good |
Last updated | 09 Sep 2024 |
Recent future growth updates
Recent updates
WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet
Sep 12Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why
Jun 12Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%
Jun 11Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding
Jun 11Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly
Apr 15Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge
Mar 04Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade
Dec 08Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Nov 26Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Nov 10What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
Sep 26These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well
Aug 26WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate
Aug 10Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?
Jun 19Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
May 12Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Mar 25At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?
Mar 13Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?
Feb 13An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued
Jan 30Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?
Dec 09Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching
Nov 20With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case
Nov 08Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?
Oct 27WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
Sep 08Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?
Aug 15We Ran A Stock Scan For Earnings Growth And WuXi Biologics (Cayman) (HKG:2269) Passed With Ease
Aug 02Estimating The Intrinsic Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Jun 29Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 23,020 | 4,865 | 2,289 | N/A | 27 |
12/31/2025 | 20,182 | 4,050 | 1,091 | N/A | 30 |
12/31/2024 | 17,880 | 3,345 | 817 | N/A | 28 |
6/30/2024 | 17,116 | 2,632 | N/A | N/A | N/A |
3/31/2024 | 17,075 | 3,016 | N/A | N/A | N/A |
12/31/2023 | 17,034 | 3,400 | 612 | 4,668 | N/A |
9/30/2023 | 16,794 | 3,776 | N/A | N/A | N/A |
6/30/2023 | 16,554 | 4,152 | N/A | N/A | N/A |
3/31/2023 | 15,911 | 4,286 | N/A | N/A | N/A |
12/31/2022 | 15,269 | 4,420 | -327 | 5,542 | N/A |
9/30/2022 | 14,179 | 4,251 | N/A | N/A | N/A |
6/30/2022 | 13,090 | 4,081 | -1,028 | 4,091 | N/A |
3/31/2022 | 11,690 | 3,735 | -2,052 | 3,761 | N/A |
12/31/2021 | 10,290 | 3,388 | -3,077 | 3,431 | N/A |
9/30/2021 | 9,183 | 3,092 | -4,006 | 2,840 | N/A |
6/30/2021 | 8,075 | 2,795 | -4,936 | 2,249 | N/A |
3/31/2021 | 6,844 | 2,242 | -4,540 | 2,065 | N/A |
12/31/2020 | 5,612 | 1,689 | -4,144 | 1,881 | N/A |
9/30/2020 | 4,967 | 1,494 | -4,049 | 1,649 | N/A |
6/30/2020 | 4,321 | 1,300 | -3,954 | 1,417 | N/A |
3/31/2020 | 4,152 | 1,157 | -2,979 | 1,312 | N/A |
12/31/2019 | 3,984 | 1,014 | -2,004 | 1,208 | N/A |
9/30/2019 | 3,535 | 922 | -1,356 | 1,035 | N/A |
6/30/2019 | 3,087 | 831 | -708 | 861 | N/A |
3/31/2019 | 2,811 | 731 | -810 | 811 | N/A |
12/31/2018 | 2,534 | 631 | -912 | 762 | N/A |
9/30/2018 | 2,277 | 520 | -1,004 | 508 | N/A |
6/30/2018 | 2,019 | 410 | -1,096 | 255 | N/A |
3/31/2018 | 1,819 | 331 | N/A | 308 | N/A |
12/31/2017 | 1,619 | 253 | N/A | 360 | N/A |
9/30/2017 | 1,429 | 177 | N/A | 320 | N/A |
6/30/2017 | 1,233 | 149 | N/A | 369 | N/A |
3/31/2017 | 1,111 | 145 | N/A | 226 | N/A |
12/31/2016 | 989 | 141 | N/A | 82 | N/A |
9/30/2016 | 889 | 171 | N/A | 162 | N/A |
12/31/2015 | 557 | 45 | N/A | 107 | N/A |
12/31/2014 | 332 | 42 | N/A | 22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2269's forecast earnings growth (18.9% per year) is above the savings rate (2.3%).
Earnings vs Market: 2269's earnings (18.9% per year) are forecast to grow faster than the Hong Kong market (11.7% per year).
High Growth Earnings: 2269's earnings are forecast to grow, but not significantly.
Revenue vs Market: 2269's revenue (10.8% per year) is forecast to grow faster than the Hong Kong market (7.3% per year).
High Growth Revenue: 2269's revenue (10.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2269's Return on Equity is forecast to be low in 3 years time (9.4%).